Docs to HHS: Keep ephedra available
This article was originally published in The Tan Sheet
Executive Summary
Prohibiting the sale of ephedra "would have a negative impact on public health in general, and on the personal health of my patients," 27 doctors say in form letters to HHS Secretary Tommy Thompson. Physicians say they "have examined the scientific literature on ephedra, which supports the weight-loss benefits and safety when...used according to current standards....I have seen positive and sometimes dramatic effects in may patients who have taken ephedra, without medically significant side effects." The signers, whose specialties include ob/gyn, urology, family medicine and internal medicine, also urge Thompson to support "labeling initiatives that specify serving limits and direct consumers to consult with health professionals before taking ephedra." Letter was drafted by Ephedra Education Council...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.